Opendata, web and dolomites

MASTFAST

Rapid production of HUMAN MAST CELLS

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MASTFAST project word cloud

Explore the words cloud of the MASTFAST project. It provides you a very rough idea of what is the project "MASTFAST" about.

validate    grow    patient    components    breaking    hampered    tissue    function    treatments    goals    proteases    syndrome    interact    angiogenesis    mouse    complement    marrow    too    implicated    ige    anaphylaxsis    release    alternative    stem    culture    ground    mucosal    damaging    produces    hematopoietic    dysfunction    enrichment    population    instead    few    skin    hesc    healing    homogenous    differentiation    dysregulation    time    phenotypic    allergic    inability    normal    pain    crispr    translate    erc    dysmotility    intestinal    damage    functional    wound    made    discovery    pathogen    medicine    adg    limit    granules    calls    weeks    mastocytoma    cas9    gene    rapid    drug    mast    molecules    fatigue    esc    airways    hescs    industry    engineered    reporter    treatment    mutant    optimize    autism    activated    bone    allergies    embryonic    341096    human    cell    escs    cells    strategies    cultures    personalized    unexpected    12    chronic    yields    connective   

Project "MASTFAST" data sheet

The following table provides information about the project.

Coordinator
THE UNIVERSITY OF EDINBURGH 

Organization address
address: OLD COLLEGE, SOUTH BRIDGE
city: EDINBURGH
postcode: EH8 9YL
website: www.ed.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 148˙914 €
 EC max contribution 148˙914 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE UNIVERSITY OF EDINBURGH UK (EDINBURGH) coordinator 148˙914.00

Map

 Project objective

Mast cells are involved in the allergic response, anaphylaxsis, wound healing and angiogenesis. When activated via IgE, damage/pathogen-induced molecules or complement components, the granules of mast cells release proteases. Dysregulation of mast cells is implicated in allergies of the skin and airways, autism, chronic fatigue syndrome, pain, mastocytoma and intestinal dysmotility. Strategies to limit the damaging effects of mast calls are needed. However, the development of novel treatments is hampered by the inability to grow mast cells rapidly and efficiently in culture. Bone marrow cell cultures typically take 12 weeks before mast cells are available for study. Even then, there are too few cells to use for drug discovery or patient-specific treatment strategies. Embryonic stem cells (ESC) represent an alternative method for the production of mast cells. An unexpected ground-breaking discovery from our ERC AdG 341096 studies aiming to produce hematopoietic stem cells, was the development of a novel method that instead produces large numbers of mast cells in a short time. Mouse ESC engineered with a unique reporter gene that allows for cell enrichment during a multi-step culture yields a homogenous population of phenotypic and functional connective tissue and mucosal mast cells. Within only 3 weeks large numbers of mast cells are generated. To translate this method for large scale rapid production of human mast cells we will 1) characterize unique human reporter ESCs made by Crispr/CAS9 state-of-the-art method; 2) optimize human mast cell production from reporter hESCs in a multi-step differentiation culture; 3) characterize/validate the function of hESC-derived mast cells (normal and mutant); 4) interact with industry to use hESC-derived mast cells for drug-discovery and studies of mast cell differentiation and dysfunction. Long-term goals include the development of mast cell treatment strategies for personalized medicine.

 Publications

year authors and title journal last update
List of publications.
2018 Mari-Liis Kauts, Bianca De Leo, Carmen Rodríguez-Seoane, Roger Ronn, Fokion Glykofrydis, Antonio Maglitto, Polynikis Kaimakis, Margarita Basi, Helen Taylor, Lesley Forrester, Adam C. Wilkinson, Berthold Göttgens, Philippa Saunders, Elaine Dzierzak
Rapid Mast Cell Generation from Gata2 Reporter Pluripotent Stem Cells
published pages: 1009-1020, ISSN: 2213-6711, DOI: 10.1016/j.stemcr.2018.08.007
Stem Cell Reports 11/4 2020-01-23

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MASTFAST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MASTFAST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ENUF (2019)

Evaluation of Novel Ultra-Fast selective III-V Epitaxy

Read More  

HydroLieve (2018)

A long-lasting non-migrating hydrogel for relieving chronic pain

Read More  

Aware (2019)

Aiding Antibiotic Development with Deep Analysis of Resistance Evolution

Read More